Skip to main content

Table 1 Sample description

From: Social brain activation during mentalizing in a large autism cohort: the Longitudinal European Autism Project

 

ASD

TD

Statistics: ASD vs. TD

Total n

205

189

 

Demographics

 Sex (male/female)

151/54

123/66

χ2(1) = 3.42, p = .079

 Age (years)

17.9 ± 5.4 (7.1–30.6)

18.0 ± 5.5 (7.6–31.0)

t(392) = .32, p = .749

 IQ (full IQ)

107.1 ± 14.2 (75.6–148.0)

108.5 ± 12.1 (76.8–142.0)

t(390) = 1.05, p = .295

 Handedness (right/left/ambidext/unknown)

146/22/8/29

131/16/4/38

χ2(3) = 3.66, p = .301

 Medication use (% of subjects)1

40.5

5.8

χ2(1) = 62.37, p < .001

In-scanner performance

 Mean framewise displacement (FD; in mm)2

.14 ± .08 (.03–.47)

.12 ± .08 (.03–.42)

t(392) = 1.88, p = .061

 Volumes with FD > 0.5 mm (%)

3.55 ± 4.74 (0–19.40)

3.17 ± 4.33 (0–19.73)

t(392) = .82, p = .412

 Signal-to-noise ratio

9.7 ± 1.3 (6.5–13.8)

9.9 ± 1.4 (6.5–13.8)

t(392) = 1.42, p = .155

 Task accuracy

.81 ±.13 (.33–1.0)

.83 ± .13 (0–1.0)

t(392) = 1.30, p = .194

Clinical characteristics

 ADI-R3

  Social interaction

15.5 ± 6.7 (0–29)

  

  Communication

12.6 ± 5.6 (0–26)

  

  RRB

4.5 ± 2.6 (0–12)

  

 ADOS-24

  Social affect

5.7 ± 2.5 (1–10)

  

  RRB

4.7 ± 2.6 (1–10)

  

  Total

5.0 ± 2.6 (1–10)

  

 SRS-2 (parent report)5

  Raw score

86.1 ± 30.6 (21–163)

19.9 ± 14.4 (1–74)

t(245) = 19.07, p < .001

T score

69.2 ± 12.1 (43–90)

45.1 ± 5.8 (37–66)

t(245) = 17.54, p < .001

 DAWBA comorbidities6

  ADHD symptoms

1.6 ± 1.6 (0–5)

.2 ± .7 (0–3)

t(211) = 7.25, p < .001

  Depression symptoms

1.1 ± 1.3 (0–5)

.4 ± .7 (0–4)

t(311) = 5.66, p < .001

  Anxiety symptoms

2.5 ± 1.3 (0–5)

1.2 ± .9 (0–4)

t(348) = 11.06, p < .001

  1. Participant characteristics, split by sample and age group. If not otherwise indicated, numbers reflect mean ± standard deviation, followed by value range (minimum–maximum)
  2. 1Percentage of participants taking medication prescribed for behavioral or neurological problems. Medication data was available for 132 ASD and 78 TD participants. See Additional file 1: Table S1 more information on medication
  3. 2Motion was assessed as mean framewise displacement according to [38]
  4. 3Autism Diagnostic Interview-Revised (ADI-R [36]) scores were computed for reciprocal interaction (social interaction), communication, and restrictive, repetitive stereotyped behaviors and interests (RRB). ADI-R scores reflect historical symptom severity (age 4–5 years) and were available for 197 ASD participants
  5. 4Autism Diagnostic Observation Schedule 2 (ADOS-2 [35]). Calibrated severity scores [39] were computed for social affect, RRB, and the overall total score. ADOS-2 scores reflect current symptom severity and were available for 198 ASD participants
  6. 5Total raw and total T score (sex and age normalized) on the Social Responsiveness Scale-2 (SRS-2 [40]). SRS-2 scores were available for 247 participants (i.e., TD adults are excluded from this measure; see Additional file 1 for analyses using self-reported SRS-2 scores). The raw SRS-2 scores were used in our analyses
  7. 6Comorbid symptoms of ADHD, depression, and anxiety were assessed with the Development and Well-Being Assessment (DAWBA [41]), generating six levels (ordinal scores 0 to 5) of prediction of the probability of a disorder (~ 0.1%, ~ 0.5%, ~ 3%, ~ 15%, ~ 50%, > 70%). DAWBA scores were available for 167 ASD and 146 TD participants for depression, 140 ASD and 73 TD participants for ADHD, and 183 ASD and 167 TD participants for anxiety
Back to article page

Molecular Autism

ISSN: 2040-2392